Mutations associated with IDH1 and IDH2 ultimately led to the reclassification of gliomas, changing them from being glioblastomas to astrocytomas (even if high grade) and oligodendrogliomas by the World Health Organization (WHO) in 2021 [1,3]. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).